Reduced intensity conditioning (RIC) allowed to offer allogeneic stem cell transplantation (alloSCT) to patients ineligible to standard conditioning. In addition to a number of disease-specific variables, the presence of comorbidities, as assessed by the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), and transplantation-associated factors affect the outcome of these patients following allSCT. We therefore investigated whether a combined risk-factor analysis predicts the overall outcome of patients with AML following RIC-alloSCT. 90 patients with AML who underwent alloSCT at our institution were analyzed. 50/90 patients (56%) were in CR1, 12/90 (15%) were in .CR1, and 26/90 (29%) had active disease. 4/90 patients (4%) had a favorable-risk karyotype, 51/90 patients (57%) or 29/90 patients (32%) had an intermediaterisk or a poor-risk karyotype. 18/90 (20%) patients had an intermediate-risk HCT-CI and 72/90 patients (80%) had an unfavorable score. 38/90 patients (42%) were transplanted from a matchedrelated donor. A matched-unrelated or a mismatched-unrelated donor was available in 36/90 patients (40%) or in 16/90 patients (18%). As a preparative regimen all patients received RIC (fludarabine 180 mg/m2 1 oral busulfane 8 mg/kg 1 antithymocyte globulin 40 mg/kg). Overall survival (OS) or disease-free survival (DFS) of all patients at 1, 3, and 5 years was 60%, 44%, and 44% or 56%, 46%, and 46%. 49/90 patients (54%) are in CR. Causes of death were relapse (23/90 patients (26%)) or TRM (18/90 patients (20%)). Depending on the presence or absence of at least one leukemiaspecific risk-factor (tAML, unfavorable-risk karyotype, .CR1) or transplantation-related risk-factor
Reduced intensity conditioning (RIC) allowed to offer allogeneic stem cell transplantation (alloSCT) to patients ineligible to standard conditioning. In addition to a number of disease-specific variables, the presence of comorbidities, as assessed by the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), and transplantation-associated factors affect the outcome of these patients following allSCT. We therefore investigated whether a combined risk-factor analysis predicts the overall outcome of patients with AML following RIC-alloSCT. 90 patients with AML who underwent alloSCT at our institution were analyzed. 50/90 patients (56%) were in CR1, 12/90 (15%) were in .CR1, and 26/90 (29%) had active disease. 4/90 patients (4%) had a favorable-risk karyotype, 51/90 patients (57%) or 29/90 patients (32%) had an intermediaterisk or a poor-risk karyotype. 18/90 (20%) patients had an intermediate-risk HCT-CI and 72/90 patients (80%) had an unfavorable score. 38/90 patients (42%) were transplanted from a matchedrelated donor. A matched-unrelated or a mismatched-unrelated donor was available in 36/90 patients (40%) or in 16/90 patients (18%). As a preparative regimen all patients received RIC (fludarabine 180 mg/m2 1 oral busulfane 8 mg/kg 1 antithymocyte globulin 40 mg/kg). Overall survival (OS) or disease-free survival (DFS) of all patients at 1, 3, and 5 years was 60%, 44%, and 44% or 56%, 46%, and 46%. 49/90 patients (54%) are in CR. Causes of death were relapse (23/90 patients (26%)) or TRM (18/90 patients (20%)). Depending on the presence or absence of at least one leukemiaspecific risk-factor (tAML, unfavorable-risk karyotype, .CR1) or transplantation-related risk-factor (alloSCT from a mismatched or an unrelated donor), patients were grouped into four subgroups: group I (HCT-CI # 4, no high-risk), group II (HCT-CI .4, no high-risk), group III (HCT-CI # 4, high-risk), and group IV (HCT-CI .4, high-risk). Projected OS in at 1, 2, and 4 years after alloSCT was 75%, 63%, and 63% (group I), 100%, 67%, and 67% (group II), 58%, 45%, and 36% (group III), or 31%, 15%, and 15% (group IV), which differed significantly between the subgroups (p 5 0.01). There was no statistically significant difference in TRM between the subgroups (p 5 0.27). This indicates that a combined risk-factor analysis incorporating disease-specific variables, transplantation-related factors, and comorbidities may predict the overall outcome of patients with AML after RIC-alloSCT. Complete remission (CR) after chemotherapy for AML is defined by \5% blasts in bone marrow (BM) and peripheral blood platelet count .100K/ml. This remains the primary goal following chemotherapy; however, many patients proceed to HSCT without ever achieving the platelet goal (CRp). With new therapies, the number of patients transplanted in CRp is increasing. We sought to determine if CRp was a worse prognosticator compared to classically-defined CR.
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Methods: A cohort of 427 patients was used. Disease status at HSCT included: first CR (CR1); second CR (CR2); first CRp (CRp1): patients with \5% BM blasts but not platelet recovery following induction chemotherapy; primary induction failure (PIF): no CR following induction therapy; CRp2: patients who after therapy for first relapse achieved \5% BM blasts but not platelet recovery; refractory (rel): patients in first relapse not responding to salvage therapy. CRp was assigned only if patients were thrombocytopenic $30 days from the last day of chemotherapy to the start of HSCT conditioning. Diagnoses included AML (n 5 376) or highrisk MDS (n 5 51). Conditioning regimens used: TBI-based (2%; n 5 8), oral/IV busulfan based-ablative regimens (61%; n 5 261), fludarabine/melphalan-based reduced intensity conditioning regimens (RIC) (36%; n 5 153), or other (1%; n 5 5). Fifty-eight percent (n 5 248) and 42% (n 5 179) of patients received matched sibling or unrelated donor (UD) HSCT, respectively
Results: Median age was 50 years (range 6-74). At time of HSCT, disease status was CR1 in 38% (n 5 164), CR2 in 24% (n 5 102), CRp1 in 11% (n 5 48), CRp2 in 7% (n 5 30), PIF 11% (n 5 47), and rel1 8% (n 5 36). Poor-risk cytogenetics were evenly distributed in patients in CR1 (39%) Vs. CRp1 (44%) and in CR2 (15%) Vs. CRp2 (24%). Fifty-one percent of patients died (n 5 219); 31% (n 5 134) progressed. Overall survival (OS) at 36-months was 49%. Among survivors, median follow-up is 42 months (range 3-131months). Hazard ratios for non-relapse mortality (NRM) and OS at 1-year (Table) favored patients receiving HSCT in CR1 (vs. CRp1 or PIF), or in CR2 (vs. CRp2 or rel1).
Conclusion: Significantly better OS and NRM were seen following HSCT for patients in CR compared to CRp. CRp conferred an intermediate prognostic status, better than refractory disease, but significantly worse than 'classic' CR. Achieving a CR prior to HSCT should remain the gold standard for patients with AML or MDS receiving allogeneic HSCT. Following allogeneic hematopoietic stem cell transplantation, GVL is likely mediated not only by alloreactive T cells, but also by donor lymphocytes recognizing tumor associated antigens overexpressed by leukemic cells. Selective expansion of tumor-specific CTLs could augment GVL without increasing the risk of GVHD. The cancer testis antigen PRAME is a potential target for adoptive immunotherapy of hematologic and solid tumors. We have shown that PRAME-CTL can be expanded ex vivo, using a combination of artificial antigen presenting cells (aAPC) (K562 cell line genetically modified to express the HLA-A*02 and costimulatory molecules) and cytokines. Four HLA-A*02 PRAME-derived epitopes have previously been identified using a proteosome mediated digestion analysis, that relying only on the major cleavage site of the immune proteosome, may limit their relevance. We have now adopted a method that uses a 125 overlapping pentadecapeptides library spanning whole PRAME protein. We evaluated whether novel immunogenic HLA-A*02-restricted epitopes can be identified and used to consistently generate polyclonal PRAME-CTL lines from healthy donors and patients with hematologic malignancies. CD81 T cells from 14 healthy donors and 5 patients with chronic myelogenenous leukemia (CML) were primed with autologous CD40L-activated B blasts loaded with the PRAME library in the presence of IL12, IL7 and IL15, and then expanded by weekly stimulation with peptide loaded aAPC and IL2. Using this approach we consistently generated PRAMECTLs in 12/14 HLA-A*02 healthy donors (526 6 101 SFC/10 5 cells as assessed by IFNg Elispot assay). Similarly, PRAMECTLs were generated from all 5 CML patients (630 6 120 SFC/ 10 5 cells). These PRAME-CTLs were also able to target autologous tumor blasts (57 6 6 IFNg SFC/10 5 ), demonstrating that the same peptides were presented physiologically. A Cr 51 release assay confirmed that the PRAME-reactive T cells were cytotoxic, lysing autologous-PHA blasts loaded with PRAME-library (63 6 14% at a 20:1 E:T ratio), but not with irrelevant library. Using subpools, we found that the responses of our expanded PRAME-CTLs were polyclonal, since they consistently released IFNg in response to 1 to 6 pentadecapeptides pools. Moreover, this approach has allowed to identify 6 potential new immunogenic 15mer peptides that are processed and presented by tumor cells, and should facilitate expansion of polyclonal PRAME-CTLs for adoptive transfer in patients with PRAME1 malignancy.
GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS OF HLA-IDENTICAL SIBLING TRANSPLANTS
Olsson, R., Remberger, M., Mattsson, J., Hassan, Z., Ringden, O. Karolinska University Hospital, Stockholm, Sweden
Four doses of methotrexate (MTX) and low-dose cyclosporine (CsA), starting at 1 mg/kg/day i.v. with early discontinuation, were given to 171 consecutive HLA-identical sibling recipients with leukaemia. Apart from MTX, retrospective controls (n 5 40) received CsA starting at 5-7.5 mg/kg/day i.v., and discontinued 1 year posttransplant. The target CsA trough levels were 100 ng/ml and 200-300 ng/ml in the low-dose and the control group, respectively. In the low-dose group, the risk of acute GVHD grades I-II was augmented (66% vs. 49%, p\0.01), whereas grades III-IV did not differ between the groups (9% vs. 8%). The risk of chronic GVHD was markedly increased in those receiving low-dose CsA (50% vs. 29%, p \ 0.01), and the cumulative proportion of relapse at 5 years post-transplant was increased in the control group (51% vs. 26%, p \ 0.01). Moreover, the 5-year survival rate was 63% in the lowdose group compared to 40% in the controls (P 5 0.04). In a multivariate analysis, low-dose CsA was the only factor associated with acute GVHD grades I-IV (RH 2.40, P 5 0.02). Significant predictors of chronic GVHD were low-dose CsA (RH 2.56, p \ 0.01), chronic myeloid leukaemia (RH 1.92, p \ 0.01), and administration of donator lymphocyte infusions (RH 1.66, P 5 0.03). The risk of relapse was counteracted by chronic GVHD (RH 0.46, p \ 0.01), whereas chronic GVHD (RH 0.53, p \ 0.01) and acute GVHD grades III-IV (RH 4.35, p \ 0.01) were the strongest factors associated with patient death. Importantly, the transplant-related mortality at 5 years post-transplant was similar in the low-dose CsA and control groups (18% and 20%, respectively, P 5 0.58). In conclusion, a low-dose CsA regimen in leukemic recipients of HLA-identical sibling transplants increases the rate of chronic GVHD, which seems to attenuate the risk of relapse, thereby improving patient survival. Shimoni, A., Rand, A., Shem-Tov, N., Yerushalmi, R., Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel Allogeneic SCT is a potentially curative treatment for acute leukemia, however relapsing disease is the major cause of treatment failure. Isolated extramedullary (IEM) relapse is considered a rare event and its characteristics and prognosis are less defined than systemic relapse. We analyzed outcomes of 356 consecutive pts with AML/MDS (n 5 277) and ALL (n 5 79) given SCT in a single institution. With a median follow-up of 30 months (range, 1-103), 149 pts relapsed (122 died). The overall survival rate was 34% (95CI, 27-41) and the cumulative incidence of relapse 47% (95CI, 42-54). 17 pts had IEM relapse (11.4% of all first relapses); CNS (n 5 6), mediastinum (n 5 2), pleura (n 5 2), skin (n 5 2), breast (n 5 2), bone (n 5 1), other soft tissue masses (n 5 2). IEM relapse occurred later after SCT than systemic relapse; median 14 (1-38) and 3 (1-59) months, respectively (p 5 0.002). Pts with an IEM relapse were younger, median age 38 and 46 years, respectively (p 5 0.02). IEM relapse occurred more commonly in ALL (23% of relapses) than MDS/AML (8%, P 5 0.02). There was a trend for higher incidence in pts transplanted in remission (16% of relapses) than in pts transplanted in active disease (8%, p 5 0.09). There was no relation to donor or conditioning type. Interestingly, among 14 pts having IEM relapse more than 3 months after SCT, 11 had a history of chronic GVHD (79%), compared with 29 of 70 pts with systemic relapse (41%, p 5 0.01). Pts with IEM relapse were most often treated with systemic chemotherapy, followed by radiation therapy and DLI when feasible. Pts with systemic relapse were treated with chemotherapy and DLI or a second SCT. Among the 17 pts with IEM relapse, 12 achieved CR (71%), 5 remained in continuous CR, 7 relapsed again, 2 systemic (both died), 5 EM (2 are in long-term remission). Among the 132 pts with systemic relapse, 35 achieved CR (27%), 14 died in remission, 7 remained in continuous CR, 14 relapsed again, 9 systemic (all died), 5 EM (1 is in long-term remission). The median survival after relapse was 2.5 and 20 months, and the 2-year OS rates 7% and 38% after systemic and IEM relapse, respectively (p 5 0.0002). In conclusion, IEM relapse of acute leukemia after SCT is relatively common. It occurs later than systemic relapse and more commonly in pts with chronic GVHD, suggestive that GVL is able to prevent systemic recurrence but is less successful in EM sites. When treated aggressively prognosis is better with IEM relapse and long-term survival is feasible.
ISOLATED EXTRA-MEDULLARY RELAPSE OF ACUTE LEUKEMIA AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT); DIFFERENT KINET-ICS AND BETTER PROGNOSIS THAN SYSTEMIC RELAPSE
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